Epstein-Barr virus associated lymphoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:31:42 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Epstein-Barr virus associated lymphoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Nanatinostat and Valganciclovir for Patients with Epstein-Barr Virus-Positive Relapsed or Refractory Lymphomas https://clinicaltrials.eu/trial/study-on-nanatinostat-and-valganciclovir-for-patients-with-epstein-barr-virus-positive-relapsed-or-refractory-lymphomas/ Wed, 29 Apr 2026 14:28:03 +0000 https://clinicaltrials.eu/trial/study-on-nanatinostat-and-valganciclovir-for-patients-with-epstein-barr-virus-positive-relapsed-or-refractory-lymphomas/ This clinical trial is focused on studying a type of cancer known as Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas. This condition involves a group of cancers that have returned or are resistant to treatment and are associated with the Epstein-Barr virus. The trial is testing a combination of two medications: Nanatinostat and Valganciclovir. Nanatinostat, also known by its code name VRx-3996, is a chemical compound taken as a coated tablet. Valganciclovir is another chemical compound used in this study, also taken orally.

The purpose of the study is to evaluate how well the combination of Nanatinostat and Valganciclovir works in treating these lymphomas. Participants in the study will receive these medications over a period of time, and their response to the treatment will be monitored. The study aims to see if the combination can reduce the size of the tumors or slow their growth. The trial will also look at how long the response lasts, the time until the next treatment is needed, and overall survival rates.

Throughout the study, participants will be closely observed to assess the effectiveness of the treatment and any side effects. The trial is designed to gather information on how the body processes the medications, including how long it takes for the drugs to reach their highest concentration in the blood and how long they stay in the system. This information will help determine the potential benefits of the treatment for patients with EBV+ relapsed/refractory lymphomas.

]]> Study on Golcadomide and R-CHOP Drug Combination for Patients with Untreated High-risk Large B-cell Lymphoma https://clinicaltrials.eu/trial/study-on-golcadomide-and-r-chop-drug-combination-for-patients-with-untreated-high-risk-large-b-cell-lymphoma/ Wed, 29 Apr 2026 14:27:19 +0000 https://clinicaltrials.eu/trial/study-on-golcadomide-and-r-chop-drug-combination-for-patients-with-untreated-high-risk-large-b-cell-lymphoma/ This clinical trial is focused on studying a type of cancer called High-risk Large B-cell Lymphoma. The study aims to compare the effectiveness and safety of a new treatment called Golcadomide when used alongside a standard chemotherapy regimen known as R-CHOP, against a placebo combined with the same chemotherapy. R-CHOP is a combination of drugs that includes Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. The purpose of the study is to see how well the cancer responds to the treatment and how long patients can live without the disease getting worse.

Participants in the study will receive either the new treatment with Golcadomide or a placebo, along with the R-CHOP chemotherapy. The study will monitor the participants over a period to see how the cancer progresses and to check for any side effects. The main goal is to measure the time it takes for the cancer to worsen or for the patient to pass away, known as Progression-Free Survival (PFS). Other aspects being evaluated include overall survival, which is the time until death from any cause, and whether the cancer completely responds to the treatment.

The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the new treatment or the placebo. This helps ensure the results are unbiased. The trial will continue until 2029, with recruitment starting in 2024. The findings from this study could provide valuable insights into the treatment of High-risk Large B-cell Lymphoma and potentially improve outcomes for patients with this type of cancer.

]]>